Litigation update (Dec. 12, 2014) — The Judicial Panel on Multidistrict Litigation has ordered the transfer of several Xarelto cases pending in federal venues around the country to the United States District Court for the Eastern District of Louisiana. Pending the court's approval, the cases are to be assigned to the Honorable Eldon E. Fallon for coordinated and consolidated pretrial proceedings. The coordinated proceeding (MDL No. 2592) has been named In re Xarelto (Rivaroxaban) Products Liability Action. Coordinating the cases will allow the Xarelto litigation to advance efficiently and offers an excellent forum in which plaintiffs from around the country can file claims resulting from injuries incurred through their use of Xarelto. In addition, the consolidation will allow some of the best attorneys in the country to work together while investigating the defendants' conduct in designing, manufacturing and marketing Xarelto. Cutter Law P.C. is pleased with the decision; we continue to evaluate Xarelto claims and will look forward to working with some of the country's leading attorneys in the Xarelto MDL.
Financial compensation may be available through a Xarelto lawsuit for individuals who have experienced internal bleeding or other severe side effects. If you or a loved one has suffered internal bleeding from taking Xarelto or a loved one has died as a result of taking the medication, give Cutter Law P.C. a call today.
Approved in 2011, Xarelto is one of the newest blood thinner medications on the market. Manufactured by Bayer Health Care and Johnson & Johnson subsidiary Janssen Pharmaceuticals, Inc. Xarelto has been widely prescribed to prevent stroke and blood clots in patients suffering from atrial fibrillation (arrhythmia of the heart), deep vein thrombosis (blood clots deep within the body) and pulmonary embolism (blood clots in the lungs). It has also been prescribed to patients who recently underwent knee or hip replacement surgery.
Plaintiffs in the Xarelto lawsuits allege serious and fatal injuries, including internal and gastrointestinal bleeding, brain hemorrhaging and hemorrhagic stroke.
Unlike traditional anticoagulants (e.g., warfarin, Coumadin) whose blood-thinning effects can be reversed by the use of vitamin K, there is no available antidote for Xarelto at this time.
While all blood thinners carry a risk of internal bleeding, Xarelto carries a significantly greater risk than the manufacturers originally indicated in their warning.
Other Claims Against Bayer And Janssen Include:
- The makers of Xarelto failed to warn patients and doctors about the risk of suffering a dangerous and potentially life-threatening side effect (severe bleeding) after taking the medication.
- Bayer and Janssen did not advise doctors on how to intervene and stabilize patients taking Xarelto should internal bleeding occur.
- The makers of Xarelto continue to market the drug as safe and effective.
Never A Fee Unless We Win
Our Sacramento injury lawyers are experienced in dangerous pharmaceuticals and product liability litigation. Contact us by calling toll free at 888-285-3333 or filling the contact form below.